Sarah S. Darwish

Sarah S. Darwish

Auto-generated profile, based on publicly available information

Sarah S. Darwish

Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo 11835, Egypt

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

27 May 2024 in Cancers
Verified
Journal Article
Open access
PDF file
NMNoha Mostafa Mohamed
Noha Mostafa Mohamed
PCPo-Jen Chen
Po-Jen Chen
SDSarah S. Darwish
Sarah S. Darwish
YSYu Chieh Su
Yu Chieh Su
MSMing-Hua Shiao
Ming-Hua Shiao
Mohammad Abdel-HalimMohammad Abdel-Halim
Mohammad Abdel-Halim
Numerous studies have reported that Dyrk1A, Dyrk1B, and Clk1 are overexpressed in multiple cancers, suggesting a role in malignant disease. Here, we introduce a novel class of group-selective kinase inhibitors targeting Dyrk1A, Dyrk1B, and Clk1. This was achieved by modifying our earlier selective Clk1 inhibitors, which were based on the 5-methoxybenzothiophene-2-carboxamide scaffold. By incorporating a 5-hydroxy group, we increased the potential for additional hydrogen bond interactions that broadened the inhibitory effect to include Dyrk1A and Dyrk1B kinases. Within this series, compounds 12 and 17 emerged as the most potent multi-kinase inhibitors against Dyrk1A, Dyrk1B, and Clk1. Furthermore, when assessed against the most closely related kinases also implicated in cancer, the frontrunner compounds revealed additional inhibitory activity against Haspin and Clk2. Compounds 12 and 17 displayed high potency across various cancer cell lines with minimal effect on non-tumor cells. By examining the effect of these inhibitors on cell cycle distribution, compound 17 retained cells in the G2/M phase and induced apoptosis. Compounds 12 and 17 could also increase levels of cleaved caspase-3 and Bax, while decreasing the expression of the antiapoptotic Bcl-2 protein. These findings support the further study and development of these compounds as novel anticancer therapeutics.

22 June 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
SDSarah S. Darwish
Sarah S. Darwish
PCPo-Jen Chen
Po-Jen Chen
MHMostafa M. Hamed
Mostafa M. Hamed
RWReem Wagdy
Reem Wagdy
SCShun-Hua Chen
Shun-Hua Chen
MEMatthias Engel
Matthias Engel
For many inflammatory diseases, new effective drugs with fewer side effects are needed. While it appears promising to target the activation of the central pro-inflammatory transcription factor NF-κB, many previously discovered agents suffered from cytotoxicity. In this study, new alkylthiourea quinazoline derivatives were developed that selectively inhibit the activation of NF-κB in macrophage-like THP−1 cells while showing low general cytotoxicity. One of the best compounds, 19, strongly inhibited the production of IL-6 (IC50 = 0.84 µM) and, less potently, of TNFα (IC50 = 4.0 µM); in comparison, the reference compound, caffeic acid phenethyl ester (CAPE), showed IC50s of 1.1 and 11.4 µM, respectively. Interestingly, 19 was found to block the translocation of the NF-κB dimer to the nucleus, although its release from the IκB complex was unaffected. Furthermore, 19 suppressed the phosphorylation of NF-κB-p65 at Ser468 but not at Ser536; however, 19 did not inhibit any kinase involved in NF-κB activation. The only partial suppression of p65 phosphorylation might be associated with fewer side effects. Since several compounds selectively induced cell death in activated macrophage-like THP−1 cells, they might be particularly effective in various inflammatory diseases that are exacerbated by excess activated macrophages, such as arteriosclerosis and autoimmune diseases.

10 November 2025 in RSC Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
MEMichael Emad
Michael Emad
RWReham Waheed
Reham Waheed
ZMZeinab Mostafa
Zeinab Mostafa
SDSarah S. Darwish
Sarah S. Darwish
RPRosa Purgatorio
Rosa Purgatorio
Mohammad Abdel-HalimMohammad Abdel-Halim
Mohammad Abdel-Halim
A novel series of pyrazolidinones and pyrazolidinediones was developed as selective COX-2 inhibitors, exhibiting anti-amyloid β, anti-tau, and neuroprotective activities.

28 April 2024 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
FMFayrouz Mustafa
Fayrouz Mustafa
Mohammad Abdel-HalimMohammad Abdel-Halim
Mohammad Abdel-Halim
RARadwa Abdel-Moniem
Radwa Abdel-Moniem
SAShahir Aziz
Shahir Aziz
SDSarah S. Darwish
Sarah S. Darwish
STSalma N. Tammam
Salma N. Tammam